Influence of CYP2C19 loss-of-function variants on the antiplatelet effects and cardiovascular events in clopidogrel-treated Chinese patients undergoing percutaneous coronary intervention

详细信息    查看全文

• 作者：Jian-Jun Zou (1) (3)
  Hong-Guang Xie (2)
  Shao-Liang Chen (4)
  Jie Tan (3)
  Ling Lin (4)
  Ying-Ying Zhao (4)
  Hai-Mei Xu (4)
  Song Lin (4)
  Juan Zhang (4)
  Guang-Ji Wang (1)
  
• 关键词：Clopidogrel ; CYP2C19 ; Polymorphism ; Platelet aggregation ; Stent thrombosis
• 刊名：European Journal of Clinical Pharmacology
• 出版年：2013
• 出版时间：April 2013
• 年：2013
• 卷：69
• 期：4
• 页码：771-777
• 全文大小：195KB
• 参考文献：1. Mega JL, Close SL, Wiviott SD, Shen L (2009) Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 360:354-62 CrossRef
  2. Xie HG, Zou JJ, Hu ZY (2011) Individual variability in the disposition of and response to clopidogrel: pharmacogenomics and beyond. Pharmacol Ther 129:267-89 CrossRef
  3. Simon T, Verstuyft C, Mary-Krause M (2009) Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 360:363-75 CrossRef
  4. Kuliczkowski W, Witkowski A, Polonski L (2009) Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J 30:426-35 CrossRef
  5. Paré G, Mehta SR, Yusuf S (2010) Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med 363:1704-714 CrossRef
  6. Pereillo JM, Maftouh M, Andrieu A (2002) Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos 30:1288-295 CrossRef
  7. Savi P, Pereillo JM, Uzabiaga MF (2000) Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 84:891-96
  8. Trenk D, Hochholzer W, Fromm MF (2008) Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 51:1925-934 CrossRef
  9. Shuldiner AR, O’Connell JR, Bliden KP (2009) Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302:849-57 CrossRef
  10. Sibbing D, Stegherr J, Latz W (2009) Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J 30:916-22 CrossRef
  11. Xie HG (1997) Direct evidence for the higher frequency of CYP2C19 allelic heterozygotes in Chinese subjects than in white subjects. Clin Pharmacol Ther 62:691-92 CrossRef
  12. Xie HG, Kim RB, Wood AJ (2001) Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 41:815-50 CrossRef
  13. Li YG, Ni L, Brandt JT (2009) Inhibition of platelet aggregation with prasugrel and clopidogrel: an integrated analysis in 846 subjects. Platelets 20:316-27 CrossRef
  14. Chang M, Dahl ML, Tybring G (1996) Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 5:358-63 CrossRef
  15. Persson I, Aklillu E, Rodrigues F (1996) S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among E-thiopians. Pharmacogenetics 6:521-26 CrossRef
  16. Bouman HJ, Parlak E, van Werkum JW, Breet NJ (2010) Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel. J Thromb Haemost 8:482-88 CrossRef
  17. Cutlip DE, Windecker S, Mehran R (2007) Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115:2344-351 CrossRef
  18. Mauri L, Hsieh WH, Massaro JM (2007) Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356:1020-029 CrossRef
  19. Chen SL, Santoso T, Zhang JJ (2011) A randomized clinical study comparing double kissing crush with provisional stenting for treatment of coronary bifurcation lesions. J Am Coll Cardiol 57:914-20 CrossRef
  20. Hulot JS, Bura A, Villard E (2006) Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108:2244-247 CrossRef
  21. Harmsze A, van Werkum JW, Bouman HJ (2010) Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation. Pharmacogenet Genomics 20:18-5 CrossRef
  22. Jeong YH, Kim IS, Park Y (2010) Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150?mg/day: results of the ACCEL-DOUBLE (Accelerated platelet inhibition by a double dose of clopidogrel according to gene polymorphism) study. JACC Cardiovasc Interv 3:731-41 CrossRef
  23. Collet JP, Hulot JS, Pena A (2009) Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373:309-17 CrossRef
  
• 作者单位：Jian-Jun Zou (1) (3)
  Hong-Guang Xie (2)
  Shao-Liang Chen (4)
  Jie Tan (3)
  Ling Lin (4)
  Ying-Ying Zhao (4)
  Hai-Mei Xu (4)
  Song Lin (4)
  Juan Zhang (4)
  Guang-Ji Wang (1)
  
  1. Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, 210009, China
  3. Division of Clinical Pharmacology, Nanjing Hospital Affiliated to Nanjing Medical University, Nanjing, 210006, China
  2. General Clinical Research Center and Division of Clinical Pharmacology, Nanjing Hospital Affiliated to Nanjing Medical University, Nanjing, 210006, China
  4. Division of Cardiology, Nanjing Hospital Affiliated to Nanjing Medical University, Nanjing, 210006, China
  
• ISSN：1432-1041

文摘

Background and objectives A large number of clinical studies have well demonstrated that the loss-of-function variant allele CYP2C19*2 is associated with attenuated response to clopidogrel and increased risk of developing stent thrombosis (ST) in white or black patients with stenting. However, similar association studies on the effect of the CYP2C19*2 and *3 variants on maximum platelet aggregation (MPA) and the risk of cardiovascular events are currently unavailable for the Chinese patients. This work was aimed at assessing the impact of the CYP2C19 *2 and *3 variants on the antiplatelet effects and adverse cardiovascular events in clopidogrel-treated Chinese patients undergoing percutaneous coronary intervention (PCI). Methods The study population consisted of 617 patients undergoing PCI. Genotypes were determined using MALDI/TOF-MS. MPA was measured by light transmittance aggregometry. The clinical end-point was the 1-year incidence of adverse cardiovascular events, including ST. Results Carriers of CYP2C19 heterozygous (*1/*2, or *1/*3; n--78) and mutant homozygous (*2/*2, *2/*3, or *3/*3, n--0) genotypes had significantly higher MPA values than noncarriers (*1/*1; n--59; P--.036 and 0.007 respectively). Moreover, the presence of the CYP2C19*2 or *3 mutant allele was significantly associated with an increased risk of developing ST, with the higher risk of ST being seen in patients homozygous for the CYP2C19*2 or *3 variant allele than in noncarriers (OR, 13.58; 95% CI, 1.49-23.31; P--.012). Furthermore, multivariate analysis revealed an independent association of the presence of CYP2C19*2 and/or *3 variant alleles with greater MPA values (P--.001) and increased risk of ST (OR, 11.67; 95% CI, 1.21-8.83; P--.022). However, there was no significant influence of CYP2C19*2 and *3 on the risk of developing other adverse cardiovascular events. Conclusions Carriage of the loss-of-function genetic variants CYP2C19*2 and *3 is significantly associated with attenuated platelet response to clopidogrel and an increased risk of ST in Chinese patients treated with stenting.